US Regulatory Affairs Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. US Regulatory Affairs Market, By Services

7.1. US Regulatory Affairs Market, by Services

7.1.1. Regulatory Consulting

7.1.1.1. Market Revenue and Forecast

7.1.2. Legal Representation

7.1.2.1. Market Revenue and Forecast

7.1.3. Regulatory Writing & Publishing

7.1.3.1. Market Revenue and Forecast

7.1.4. Product Registration & Clinical Trial Applications

7.1.4.1. Market Revenue and Forecast

7.1.5. Other Services

7.1.5.1. Market Revenue and Forecast

Chapter 8. US Regulatory Affairs Market, By Category

8.1. US Regulatory Affairs Market, by Category

8.1.1. Drugs

8.1.1.1. Market Revenue and Forecast

8.1.2. Biologics

8.1.2.1. Market Revenue and Forecast

8.1.3. Medical Devices

8.1.3.1. Market Revenue and Forecast

Chapter 9. US Regulatory Affairs Market, By Indication

9.1. US Regulatory Affairs Market, by Indication

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast

9.1.2. Neurology

9.1.2.1. Market Revenue and Forecast

9.1.3. Cardiology

9.1.3.1. Market Revenue and Forecast

9.1.4. Immunology

9.1.4.1. Market Revenue and Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Forecast

Chapter 10. US Regulatory Affairs Market, By Stage

10.1. US Regulatory Affairs Market, by Stage

10.1.1. Preclinical

10.1.1.1. Market Revenue and Forecast

10.1.2. Clinical studies

10.1.2.1. Market Revenue and Forecast

10.1.3. PMA

10.1.3.1. Market Revenue and Forecast

Chapter 11. US Regulatory Affairs Market, By Service Provider

11.1. US Regulatory Affairs Market, by Service Provider

11.1.1. In-house

11.1.1.1. Market Revenue and Forecast

11.1.2. Outsourced

11.1.2.1. Market Revenue and Forecast

Chapter 12. US Regulatory Affairs Market, By Company

12.1. US Regulatory Affairs Market, by Company

12.1.1. Small

12.1.1.1. Market Revenue and Forecast

12.1.2. Medium

12.1.2.1. Market Revenue and Forecast

12.1.3. Large

12.1.3.1. Market Revenue and Forecast

Chapter 13. US Regulatory Affairs Market, By End User

13.1. US Regulatory Affairs Market, by End User

13.1.1. Medical Device Companies

13.1.1.1. Market Revenue and Forecast

13.1.2. Pharmaceutical Companies

13.1.2.1. Market Revenue and Forecast

13.1.3. Biotechnology Companies

13.1.3.1. Market Revenue and Forecast

Chapter 14. US Regulatory Affairs Market, Regional Estimates and Trend Forecast

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Services

14.1.8.2. Market Revenue and Forecast, by Category

14.1.8.3. Market Revenue and Forecast, by Indication

14.1.8.4. Market Revenue and Forecast, by Stage

14.1.8.5. Market Revenue and Forecast, by Service Provider

14.1.8.6. Market Revenue and Forecast, by End User

14.1.8.7. Market Revenue and Forecast, by Company

Chapter 15. Company Profiles

15.1. Accell Clinical Research, LLC

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Genpact

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Promedica International

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. WuXi AppTec, Inc.

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Criterium, Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. PRA Health Sciences

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Medpace

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Charles River Laboratories International

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. PAREXEL International Corp., Inc.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Freyr

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms